Therefore, the current report presents a cohort study investigating the association between VEGF polymorphisms −2578C/A, −1154G/A and −634C/G, and the clinical outcome of RCC patients, as well as the interaction of the VEGF polymorphisms with tumor stage, metastasis and size. This evidence concerns the gene VEGFA and renal cell carcinoma.